A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML

The treatment landscape of AML is evolving with promising therapies entering clinical translation, yet patient responses remain heterogeneous and biomarkers for tailoring treatment are lacking. To understand how disease heterogeneity links with therapy response, we determined the leukemia cell hierarchy make-up from bulk transcriptomes of over 1000 patients through deconvolution using single-cell reference profiles of leukemia stem, progenitor, and mature cell types. Leukemia hierarchy composition was associated with functional, genomic, and clinical properties and converged into four overall classes, spanning Primitive, Mature, GMP, and Intermediate. Critically, variation in hierarchy composition along the Primitive vs GMP or Primitive vs Mature axes were associated with response to chemotherapy or drug sensitivity profiles of targeted therapies, respectively. A 7-gene biomarker derived from the Primitive vs Mature axis was predictive of patient response to 105 investigational drugs. Thus, hierarchy composition constitutes a novel framework for understanding disease biology and advancing precision medicine in AML.

[1]  B. Haibe-Kains,et al.  Evaluation of statistical approaches for association testing in noisy drug screening data , 2021, BMC Bioinformatics.

[2]  J. Dick,et al.  CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells. , 2020, Blood.

[3]  Fabian J. Theis,et al.  Query to reference single-cell integration with transfer learning , 2020, bioRxiv.

[4]  Y. Saeys,et al.  A scalable SCENIC workflow for single-cell gene regulatory network analysis , 2020, Nature Protocols.

[5]  J. Danska,et al.  SIRPαFc treatment targets human acute myeloid leukemia stem cells , 2019, Haematologica.

[6]  Mike Tyers,et al.  Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. , 2019, Cancer cell.

[7]  Guo-Cheng Yuan,et al.  Accurate estimation of cell-type composition from gene expression data , 2019, Nature Communications.

[8]  Jae Hoon Sul,et al.  Accurate estimation of cell composition in bulk expression through robust integration of single-cell information , 2019, Nature Communications.

[9]  Verena I Gaidzik,et al.  Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation , 2019, Nature Communications.

[10]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[11]  G. Pinkus,et al.  Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity , 2019, Cell.

[12]  G. Sauvageau,et al.  Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. , 2019, Blood advances.

[13]  Michael I. Jordan,et al.  Probabilistic harmonization and annotation of single‐cell transcriptomics data with deep generative models , 2019, bioRxiv.

[14]  S. Corey,et al.  Peering through zebrafish to understand inherited bone marrow failure syndromes , 2018, Haematologica.

[15]  G. Boucher,et al.  Genetic characterization of ABT-199 sensitivity in human AML , 2018, Leukemia.

[16]  Christopher A. Miller,et al.  Immune Escape of Relapsed AML Cells after Allogeneic Transplantation , 2018, The New England journal of medicine.

[17]  Vincent A. Traag,et al.  From Louvain to Leiden: guaranteeing well-connected communities , 2018, Scientific Reports.

[18]  Beth Wilmot,et al.  Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.

[19]  Charles Y. Lin,et al.  Mutant NPM1 Maintains the Leukemic State through HOX Expression. , 2018, Cancer cell.

[20]  Nancy R. Zhang,et al.  Bulk tissue cell type deconvolution with multi-subject single-cell expression reference , 2018, Nature Communications.

[21]  P. Stephens,et al.  Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling , 2018, Oncotarget.

[22]  J. Krosl,et al.  Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin , 2018, Leukemia.

[23]  T. Hughes,et al.  The Human Transcription Factors , 2018, Cell.

[24]  Fabian J Theis,et al.  SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.

[25]  G. Boucher,et al.  Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity , 2017, Clinical Cancer Research.

[26]  Gary D Bader,et al.  Tracing the origins of relapse in acute myeloid leukaemia to stem cells , 2017, Nature.

[27]  J. Aerts,et al.  SCENIC: Single-cell regulatory network inference and clustering , 2017, Nature Methods.

[28]  G. Boucher,et al.  Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. , 2016, Blood.

[29]  Joshua F. McMichael,et al.  Visualizing tumor evolution with the fishplot package for R , 2016, bioRxiv.

[30]  Francine E. Garrett-Bakelman,et al.  Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia , 2016, Nature Medicine.

[31]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[32]  G. Sauvageau,et al.  Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets , 2016, Blood Cancer Journal.

[33]  G. Boucher,et al.  RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. , 2016, Blood.

[34]  J. Marioni,et al.  Pooling across cells to normalize single-cell RNA sequencing data with many zero counts , 2016, Genome Biology.

[35]  J. Dick,et al.  An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers. , 2016, Cancer research.

[36]  G. Boucher,et al.  Identification of MYC mutations in acute myeloid leukemias with NUP98–NSD1 translocations , 2016, Leukemia.

[37]  P. Linsley,et al.  MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data , 2015, Genome Biology.

[38]  Fabian J. Theis,et al.  Diffusion maps for high-dimensional single-cell analysis of differentiation data , 2015, Bioinform..

[39]  G. Boucher,et al.  The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias , 2015, Nature Genetics.

[40]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[41]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[42]  Shankar Vembu,et al.  PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors , 2015, Genome Biology.

[43]  Christopher A. Miller,et al.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.

[44]  Stephen R. Piccolo,et al.  A single-sample microarray normalization method to facilitate personalized-medicine workflows. , 2012, Genomics.

[45]  H. Dombret,et al.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.

[46]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[47]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[48]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[49]  J. Griffin,et al.  Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties. , 1983, Blood.

[50]  J. Till,et al.  The cellular basis of self renewal in culture by human acute myeloblastic leukemia blast cell progenitors , 1980, Journal of cellular physiology.

[51]  M. Minden,et al.  Self-renewal in culture of proliferative blast progenitor cells in acute myeloblastic leukemia. , 1979, Blood.

[52]  J. Fried,et al.  Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given single injections of tritiated thymidine. , 1967, The Journal of clinical investigation.

[53]  J. Till,et al.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. , 1961, Radiation research.

[54]  Austin E. Gillen,et al.  Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia , 2020 .

[55]  A. Letai,et al.  Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice , 2016, Leukemia.

[56]  G. Sauvageau,et al.  EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. , 2015, Blood.

[57]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[58]  E. McCulloch.  Stem Cells in Normal and Leukemic Hemopoiesis , 2005 .

[59]  B. Löwenberg,et al.  On the maturation order of AML cells: a distinction on the basis of self-renewal properties and immunologic phenotypes. , 1984, Blood.

[60]  M. Minden,et al.  Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML). , 1978, Blood.

[61]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .